Press Releases July 13, 2026 08:30 AM

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

Enovis launches CT-RevitL™, an advanced veterinary laser therapy system enhancing animal care and clinical outcomes

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
ENOV

Enovis Corporation's Companion Animal Health division has launched CT-RevitL™, a next-generation photobiomodulation (PBM) laser therapy system in the U.S. Designed to deliver deeper, faster, and more consistent therapeutic outcomes, CT-RevitL integrates COMPASS technology for precise and calibrated dosing. This innovation supports veterinary practices by improving clinical results, efficiency, and client satisfaction while fostering growth in non-drug treatment offerings.

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
ENOV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CT-RevitL™ improves veterinary laser therapy with enhanced clinical performance and mobility, backed by over 150 published studies.
  • The system's COMPASS technology provides intelligent treatment guidance ensuring precise and consistent dosing, reducing variability across users.
  • Launch supports veterinary practice growth by expanding treatment options, encouraging repeatable protocols, and promoting recurring demand for non-drug care.
  • Sectors impacted include veterinary healthcare, medical technology, animal therapeutics, and pet care markets.
  • CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy
  • Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals

DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.

Laser therapy is one of the fastest-growing modalities in veterinary medicine, used to manage pain, accelerate tissue healing, reduce inflammation and support post-operative recovery across a wide range of musculoskeletal and soft-tissue conditions.¹ As pet owners increasingly seek drug-sparing alternatives and practices look for tools that improve both clinical outcomes and practice efficiency, demand for advanced laser therapy continues to grow.²

Companion Animal Health, an Enovis business and the U.S. market leader in veterinary therapeutic laser technology, has spent more than 15 years advancing the science and clinical application of PBM laser therapy. CT-RevitL uses Companion’s new COMPASS technology, an intelligent treatment guidance system that delivers precise, calibrated dosing to help reduce treatment variability and support consistent application across users. By making high-powered laser therapy simpler to deliver and easier to integrate into everyday practice workflows, COMPASS helps veterinary teams provide treatment with greater confidence and efficiency.³

"CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care," said Terry Ross, Group President of Enovis’ Prevention & Recovery business segment, which includes Companion Animal Health. "We have been the trusted partner of veterinary teams across the U.S. for nearly two decades, and CT-RevitL extends that leadership by giving practitioners a more intuitive and consistent way to deliver laser therapy. It is a meaningful step forward for the pets we care for, the practices that rely on us, and the broader advancement of laser therapy as a standard of care in veterinary medicine."

Beyond its clinical applications, CT-RevitL is designed to support practice growth by expanding treatment offerings, encouraging repeatable protocols and helping practices generate recurring demand for non-drug care. By supporting routine use across a broad range of conditions, the system can help practices improve return on investment, strengthen client satisfaction and differentiate themselves as providers of advanced veterinary care.

CT-RevitL is available to veterinary practices across the United States beginning July 13, 2026, with international availability anticipated in subsequent phases. The launch is supported by a comprehensive clinical education program and ongoing partnership from Companion’s veterinary specialists. For more information, visit www.companionanimalhealth.com.

About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com.

About Companion Animal Health
Companion Animal Health, a division of Enovis, is a global leader in veterinary medical technology and education. We believe in enhancing animal well-being by providing advanced, non-invasive treatments—such as laser therapy and targeted regenerative solutions—that promote faster healing and pain management. Headquartered in Newark, Delaware, we support veterinary professionals worldwide with innovative equipment and clinical support. For more information, visit www.companionanimalhealth.com.

Trademark Notice
Enovis, CT-RevitL, and Companion Animal Health are trademarks or registered trademarks of Enovis™ Corporation or its affiliates.

Media Contact
Cristina Pasquino
Enovis Corporation
[email protected]

References

¹ Riegel RJ, Godbold JC. Laser Therapy in Veterinary Medicine: Photobiomodulation. Wiley-Blackwell; 2017.

² Pryor B, Millis DL. Therapeutic laser in veterinary medicine. Vet Clin North Am Small Anim Pract. 2015;45(1):45-56. doi:10.1016/j.cvsm.2014.09.003.

³ Companion Animal Health. Publications: scientific studies on photobiomodulation and laser therapy. Available at: publications.companionanimalhealth.com.

Attachment

  • Companion Animal Health CT-RevitL™

Risks

  • Adoption rates may vary among veterinary practices, potentially affecting anticipated market penetration and revenue growth.
  • Regulatory and reimbursement landscapes for veterinary laser therapy could evolve, impacting product usage and sales.
  • Competition from other veterinary therapeutic technologies may pressure market share and margins.

More from Press Releases

General Fusion Becomes First Publicly Listed Fusion Company Jul 13, 2026 Old National Bank Foundation celebrates 20 years, $40+ million in Community Impact Jul 13, 2026 Genco Shipping & Trading Limited Comments on Extension of $24.80 Per Share Tender Offer by Diana Shipping Jul 13, 2026 Exyn COO Ben Williams to Discuss the Future of Autonomous Robotics in Live Industry Interview: The Future of 3D Scanning is Autonomous Jul 13, 2026 Scott Gill Appointed Vice President of Technology and Operations at TEGNA Jul 13, 2026